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A B S T R A C T
Inﬂammatory bowel disease (IBD) affects millions of people worldwide but its pathophysiology remains
unclear. Therefore, experimental models of colitis have contributed crucially for the understanding of
IBD, and also in the investigations for effective therapies. Herein we investigated the kinetics of
inﬂammatory mediator production and cell inﬁltration during acute and chronic dextran sodium sulfate
(DSS)-induced colitis. The induction phases with DSS were characterized by severe disease activity with
massive colonic polymorphonuclear inﬁltration and increased levels of tumor necrosis factor-a (TNF-a),
keratinocyte-derived chemokine (CXCL1/KC), interleukin (IL)-17 and vascular adhesion molecule-1
(VCAM-1). Interestingly, in the recovery periods, we found marked increase of anti-inﬂammatory
mediators IL-10, IL-4, transforming growth factor-b (TGF-b) and cyclooxygenase 2 (COX-2) that seems
be essential for the resolution of intestinal inﬂammation. Furthermore, nuclear factor kB (NFkB) and
regulatory T cell marker forkhead box P3 (FoxP3) were increased gradually during experimental colitis,
demonstrating a discrepant proﬁle response and evident immune disbalance in the chronic phase of
intestinal mucosal inﬂammation. Taken together, these results provide valuable information for studies
on DSS-induced colitis and especially for the identiﬁcation of biomarkers that predict disease course and
possible therapeutic interventions.
 2012 Elsevier Inc. 
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Crohn’s disease (CD) and ulcerative colitis (UC) are the two major
forms of inﬂammatory bowel disease (IBD), and are characterized by
an abnormal cell inﬂux to the intestinal tissues and massive release
of pro-inﬂammatory mediators [1]. These events are crucial for
intestinal inﬂammation and may induce an atypical signaling
pathway leading to de-regulation of intestinal homeostasis [2,3].
Besides the altered immune response driven by microbial factors in
the enteric environment, a combination of many other factors such
as genetic susceptibility and environmental conditions are thought
to be necessary for clinical expression of the disease [2,4,5].
Animal models have greatly contributed to our understanding
about the factors that inﬂuence IBD development and they also
provide helpful tools for emergent novel therapeutic strategies§ This study was supported by Conselho Nacional de Desenvolvimento Cientı´ﬁco
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Open access under the Elsevier OA license.[6]. One of the most common IBD-related models is the dextran
sulfate sodium (DSS)-induced colitis. The administration of DSS
polymers in drinking water induces acute colitis [7] and is useful
for studying the involvement of innate immune mechanisms.
Indeed, the great majority of published papers have used animal
models in acute periods, but CD and UC are known as chronic
pathologies. Therefore an important feature of this model is that
the administration of repetitive cycles of DSS leads to chronic
intestinal inﬂammation, which permits important observations
about the adaptive immune system [8] and allows studies of
mediators and cell Inﬂux involved in the chroniﬁcation process of
IBD.
The inﬂammatory mediators responsible for the pathogenesis
of DSS-induced colitis are of a heterogeneous nature, and several
research groups have reported contrasting results, particularly for
cell inﬂux and protein expression. Such discrepant ﬁndings may at
least in part be explained by the speciﬁc methodology used,
different time points at which analyses were performed, mice
strain susceptibility and/or DSS solution concentration. Further-
more, to the best of our knowledge very few studies aimed to
clarify the kinetics of inﬂammatory events mediating acute and
chronic phases of DSS-induced colitis.
In this context, the present study aimed to assess cellular inﬂux
and inﬂammatory markers during the acute and chronic phases of
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differences between the induction phase and the recovery period
which may be valuable for future evolution of the DSS colitis model
and, particularly, may provide strong evidence for the identiﬁca-
tion of biomarkers relevant for the prediction of disease course and
the design of possible therapeutic interventions.
2. Materials and methods
2.1. Animals
Male BALB/c mice (eight to 10 weeks of age) were obtained
from the Laborato´rio de Farmacologia Experimental (LAFEX),
Universidade Federal de Santa Catarina (UFSC, Floriano´polis, SC,
Brazil), and housed in collective cages at 22  1 8C under a 12-h
light/dark cycle (lights on at 07:00 h) with free access to laboratory
chow and tap water. Experiments were performed during the light
phase of the cycle. The experimental procedures were previously
approved by the UFSC’s Committee on the Ethical Use of Animals
(CEUA, protocol PP00568), where the study was carried out, and
were conducted in accordance with Brazilian regulations on animal
welfare.
2.2. DSS-induced colitis
Male BALB/c mice (n = 6–8 per group) were provided with a
solution of ﬁltered water containing 2% dextran sodium sulfate
(DSS) (MW 36,000–50,000) (MP Biomedicals, Solon, OH, USA) ad
libitum over a ﬁve-day period. Every other day, the total of 200 ml
of 2% DSS solution was replenished. The total volume of DSS
solution consumed per mouse was proximally 4.2 ml/day. No
differences between experimental groups were observed. Follow-
ing the ﬁrst ﬁve-day period (cycle 1), DSS was replaced with
normal drinking water for 10 days and at the end of the ﬁfteenth
day the animals were provided with a new cycle of 2% DSS for a
ﬁve-day period (cycle 2). At the end of DSS cycle 2, the solution was
replaced with normal drinking water for a further 10 days and then
the animals were euthanized on the thirtieth day (see scheme in
Fig. 1). Control mice received only drinking water. All animals were
examined once a day and the disease activity index (DAI) was
assessed as previously described [9,10]. DAI was the combined
score of weight loss, stool consistency and bleeding. Scores were
deﬁned as follows: stool consistency was graded zero for no
diarrhea, two for loose stool that did not stick to the anus, and four
for liquid stool that did stick to the anus. The Feca-cult kit (INLAB,
Sa˜o Paulo, SP, Brazil) was used for detect the presence of fecal blood
and the data was graded zero for none, two for moderate and fourFig. 1. Acute and chronic phases of DSS-induced colitis. Male Balb/c mice received
DSS (2%) for ﬁve consecutive days in drinking water. On day 5 DSS was removed and
replaced by ﬁltered water, which was supplied for 10 days. After this period,
animals were conditioned to a new DSS 2% cycle for ﬁve more days, followed by 10
days of ﬁltered water, resulting in a total of 30 days of experimental protocol. The
DSS regime phase was designated as the ‘‘induction phase,’’ whereas the ﬁltered
water offer periods were called the ‘‘recovery phase.’’.for gross bleeding. For weight loss, a value of zero was assigned if
body weight remained within 1% of baseline or higher, one for
greater than 1–5% loss, two for greater than 5–10% loss, three for
greater than 10–15% loss and four for weight loss greater than 15%.
At the end of each period (ﬁfth, ﬁfteenth, twentieth and thirtieth
day), the colons were removed for length measurement and then
frozen at 70 8C for future analysis.
2.3. Myeloperoxidase, eosinophil peroxidase and N-
acetylglucosaminidade assays
Neutrophil, eosinophil and macrophage inﬁltration in the
colon were assessed indirectly by measuring the myeloperoxidase
(MPO), eosinophil peroxidase (EPO) and N-acetylglucosaminidase
(NAG) activities. MPO, EPO and NAG were performed as previously
described [11]. Colon tissue segments were homogenized in 5%
EDTA/NaCl buffer (pH 4.7) and centrifuged at 10,000  g for
15 min at 4 8C. The pellet was resuspended in 0.5% hexadecyl
trimethyl ammonium bromide buffer (pH 5.4) and the samples
were frozen in liquid nitrogen and thawed three times. After
thawing, the samples were similarly centrifuged and 25 ml of the
supernatant was used for the MPO, EPO and NAG assays. The MPO
enzymatic reaction was assessed by addition of 1.6 mM tetra-
methylbenzidine (TMB), 80 mM NaPO4, and 0.3 mM hydrogen
peroxide (H2O2); the EPO by 1.5 mM O-phenylenediamine (OPD),
0.075 mM Tris-HC, and 6.6 mM H2O2; and the NAG activity by
2.25 mM p-nitrophenil-2-acetamide-D-glucopiranoside, and
50 mM citrate buffer (pH 4.5). The absorbance was measured
spectrophotometrically at 690, 490 and 405 nm for MPO, EPO and
NAG respectively, and the results expressed in optical density per
milligram of tissue.
2.4. Determination of cytokine levels
Brieﬂy, colon segments were homogenized in phosphate buffer
containing 0.05% Tween 20, 0.1 mM phenylmethylsulphonyl
ﬂuoride, 0.1 mM benzethonium chloride, 10 mM EDTA and 20 UI
aprotinin A. The homogenate was centrifuged at 3000  g for
10 min, and the supernatants were stored at 70 8C for further
analysis. Tumor necrosis factor a (TNF-a), interleukin (IL)-1b, IL-
12, IL-10, IL-4, keratinocyte-derived chemokine (CXCL1/KC) and
transforming growth factor b (TGF-b) levels were evaluated with
enzyme-linked immunosorbent assay (ELISA) kits from R&D
Systems according to the manufacturer’s recommendations. The
amount of protein in each sample was measured with the Bradford
method [12].
2.5. RNA extraction and real-time PCR
Total RNA from colons was extracted with the SV Total RNA
Isolation System Z3100 (Promega, Madison, WI, USA) according to
the manufacturer’s recommendations and its concentration was
determined with a NanoDrop 1100 (NanoDrop Technologies,
Wilmington, DE, USA). An amount of 100 ng of total RNA was used
for cDNA synthesis. A reverse transcription assay was performed as
described in the M-MLV Reverse Transcriptase protocol according to
the manufacturer’s instructions. cDNA was ampliﬁed in duplicate
with the TaqMan1 Universal PCR Master Mix Kit with speciﬁc
TaqMan Gene Expression target genes, the 30 quencher MGB and
FAM-labeled probes for mouse IL-17 (Mm00439618_m1), formyl-
peptide receptor 2 (FPR2/ALX) (Mm00484464_s1), forkhead box P3
(FoxP3) (Mm00475165_m1), interleukin-2 receptor (CD25/IL-2R)
(Mm01340213), intercellular adhesion molecule 1 (ICAM-1)
(Mm005616024_g1), vascular cell adhesion molecule 1 (VCAM-1)
(Mm01320970_m1), cyclooxygenase 2 (COX-2) (Mm01307334_g1)
and GAPDH (NM_008084.2) that was used as an endogenous control
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Optical Reaction Plate (Applied Biosystems, Foster City, CA, USA).
The thermocycler parameters were as follows: 50 8C for 2 min, 95 8C
for 10 min, 50 cycles of 95 8C for 15 s and 60 8C for 1 min. Expression
of the target genes was calibrated against conditions found in control
animals (i.e. animals that received vehicle).
2.6. Flow cytometric analysis
Mesenteric lymph nodes (MLN) obtained from each animal
group were macerated in RPMI 1640 medium and ﬁltered through
a 220-mm ﬁlter. The resulting suspension was centrifuged at
1500  g for 7 min, the supernatant was discarded, and the cell
pellet was resuspended in RPMI 1640 medium supplemented with
10% fetal bovine serum, 20 mM HEPES, 3  105 M 2-mercap-
toethanol, 100 U/ml penicillin and 100 mg/ml streptomycin. The
cells were incubated with the following antibodies for 20 min at
4 8C: anti-CD4-PerCP, anti-CD8a-APC and anti-CD25-PE. The data
were collected with FACSCanto II (BD Biosciences) and analyzed by
means of FlowJo (version 7.5) software.
2.7. Preparation of cytosolic and nuclear fractions
The colonic tissue was removed ﬁve, 15, 20 and 30 days after
the beginning of DSS administration and homogenized in ice-cold
lysis buffer containing 10 mM HEPES, pH 7.4; 2 mM MgCl2;
10 mM KCl; 1 mM PMSF; 1 mg/mL leupeptin; 1 mg/mL aprotinin,
1 mM sodium orthovanadate; 10 mM b-glycerophosphate;
50 mM sodium ﬂuoride and 1 mM dithiothreitol (DTT). The
homogenates were chilled on ice, centrifuged at 14,000  g for
45 min and the supernatant containing the cytosolic fraction was
collected for posterior protein concentration determination. The
pellet was reconstituted with lysis buffer and 0.1% Triton X. After
centrifugation (14,000  g for 45 min), the supernatant contain-
ing the membrane-rich fraction was dispensed and the pellet was
reconstituted again with lysis buffer and 25% glycerol. After
centrifugation, the supernatant containing the nuclear fraction
was collected and the protein concentration was determined by
the standard Bradford method. The supernatants containing the
cytosolic and nuclear-rich fractions were stored at 70 8C until
analysis.
2.8. Western blot analysis
Equivalent amounts of protein were mixed in a buffer
containing 200 mM Tris, 10% glycerol, 2% SDS, 2.75 mM; b-
mercaptoethanol and 0.04% bromophenol blue and boiled for
5 min. Proteins were resolved in a 10% SDS gel by electrophoresis.
After transfer to a polyvinylidene ﬂuoride membrane, the blots
were assembled directly into a Snap i.d. Protein Detection System
(Millipore Corporation, Billerica, MA, USA) blot holder for
immunodetection The ﬁlters were blocked with 1% bovine serum
albumin – TBS-T buffer (Tris-buffered saline solution – 20 mM Tris,
pH 7.5, 150 mM NaCl, 0.1% Tween 20 surfactant). Filters were then
probed with speciﬁc primary antibodies anti-p-IkBa, anti-p-p65
and anti-lamin A/C (1:200), for 10 min at room temperature. The
blots were washed three times with TBS-T buffer. After washing,
membranes were incubated with horseradish peroxidase (HRP)
conjugated goat anti-mouse IgG secondary antibody (1:800) or
horseradish peroxidase (HRP) conjugated donkey anti-rabbit IgG
secondary antibody (1:800) for 10 min at room temperature. The
membranes were washed again with TBS-T and then the
immunocomplexes were visualized with the ECL chemilumines-
cence detection system. Band density measurements were
obtained with Scion Image Software (Scion Corporation, Frederick,
MD, USA).2.9. Drugs and reagents
DSS was obtained from MP Biomedicals (Solon, Ohio, USA).
Monoclonal mouse anti-phospho-p65 NF-kB, monoclonal mouse
anti-IkBa and anti-lamin A/C were purchased from Cell Signaling
Technology, Inc. (Beverly, MA, USA). Horseradish peroxidase (HRP)
conjugated goat anti-mouse IgG secondary antibody was acquired
from Promega Corporation (Madison, WI, USA) and horseradish
peroxidase (HRP) conjugated donkey anti-rabbit IgG secondary
antibody was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). The ECL chemiluminescence detection
system was provided by GE Healthcare (Sa˜o Paulo, SP, Brazil).
Hydrogen peroxide, Tween 20, EDTA, aprotinin, phosphate-
buffered saline, tetramethylbenzidine (TMB), O-phenylenediamine
(OPD), p-nitrophenil-2-acetamide-D-glucopiranoside (NAG),
HTAB, PMSF, benzethonium chloride, sodium orthovanadate, b-
glycerophosphate and sodium ﬂuoride were purchased from
Sigma Chemical Co. (St Louis, MI, USA). Sodium chloride was
obtained from Cromadine (Sa˜o Paulo, SP, Brazil). NaPO4 and MgCl2
were purchased from Synth (Diadema, SP, Brazil). Bradford reagent
and Tris–HCl was obtained from BioAgency (Sa˜o Paulo, SP, Brazil).
Sodium citrate and Triton X was purchased from Vetec (Duque de
Caxias, RJ, Brazil). Fetal bovine serum, RPMI, HEPES, 2-mercap-
toethanol, penicillin, streptomycin and dithiothreitol (DTT) were
obtained from Gibco (Grand Island, NY, USA). Potassium chloride
was purchased from Merck (Rio de Janeiro, RJ, Brazil). Mouse TNF-
a, IL-1b, IL-12, IL-10, IL-4, CXCL1/KC and TGF-b DuoSet kits were
obtained from R&D Systems (Minneapolis, MN, USA). SV Total RNA
Isolation System, M-MLV reverse transcriptase and glycerol were
purchased from Promega (Madison, WI, USA). Primers and probes
for mouse TNF-a, IL-1b, CXCL1/KC, IL-17, IL-10, TGF-b, FPR2/ALX,
FoxP3, CD25/IL-2R, ICAM-1, VCAM-1, COX-2, GAPDH and Taq-
Man1 Universal PCR Master Mix Kit were purchased from Applied
Biosystems (Foster City, CA, USA). Antibodies for CD4-PerCP and
anti-CD8a-APC were purchased from Caltag Laboratories (Burlin-
game, CA, USA) and anti-CD25-PE from BD PharmingenTM (San
Jose, CA, USA).
2.10. Data analysis
All data are expressed as the mean  S.E.M. For non-parametric
data, a Kruskal–Wallis test followed by a Dunn’s test was used. For
parametric data, the statistical differences between groups were
determined by one-way ANOVA followed by a Student Newman–
Keuls test. Statistical analyses were performed with GraphPad
Prism1 4 software (GraphPad Software Inc., San Diego, CA). A P-
value of less than 0.05 (P < 0.05) was considered to be statistically
signiﬁcant.
3. Results
3.1. Disease activity and colonic myeloid cellular inﬁltration in acute
and chronic DSS-induced colitis
In order to characterize acute and chronic colonic inﬂamma-
tion, mice were subjected to two separate cycles of ﬁve-day DSS
administration, followed by normal drinking water for 10 days
(recovery phase), the disease activity index (DAI) and body
weight change were analyzed every other day for 30 days and a
number of inﬂammatory parameters were observed at the end of
each DSS cycle and at the end of the recovery phases (day 5, day
15, day 20 and day 30). In this study we opted by use a solution of
2% DSS, since previous data of our lab showed that this
concentration caused a moderate colitis that not interfere with
mice survival in the acute period, allowing the conduction of a
new cycle of DSS.
Fig. 2. Disease activity index and myeloid cellular migration during DSS-induced colitis. The animals were subjected to two cycles of 2% DSS, from day zero to day 5 (cycle 1),
and from day 15 to day 20 (cycle 2). The recovery periods correspond to treatment with ﬁltered water (H2O), from day 5 to day 15 and from day 20 to day 30. (A) Two percent
DSS solution in drink water increased the Disease Activity index (DAI) in the ﬁrst cycle of DSS, which was attenuated after the ﬁrst phase of recovery with ﬁltered water.
Likewise, after the second cycle of DSS, DAI was signiﬁcantly increased, and remained signiﬁcantly elevated at the end of the second phase of recovery (day 30). (B) Similarly to
the results in panel A, DSS solution caused weight loss in the ﬁrst cycle of DSS, which returned to baseline after the recovery period. After the second cycle of DSS weight loss
was also observed. (C) In the ﬁrst cycle of DSS the colon was signiﬁcantly shortened compared to the control group; while at the end of ﬁfteenth day the colon length was
signiﬁcantly restored. After the second cycle of DSS colon was again shortened until day 30. Furthermore, the inﬁltration of neutrophils, eosinophils and macrophages into the
tissue of the colon were evaluated indirectly by measuring the MPO, EPO and NAG activities, respectively. (D) MPO activity increased after the ﬁrst and second DSS cycle, and
still increased 30 days after the beginning of the experimental protocol. (E) At the end of cycles 1 and 2 (ﬁve and 20 days, respectively), but not in recovery phases, colonic
tissue showed high levels of EPO. (F) The NAG activity showed an increase only 30 days after initiation of treatment with DSS. Data are reported as means  S.E.M. of six to eight
mice per group. #P < 0.05 versus control group; *P < 0.05 versus selected groups.
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increase in DAI score, characterized by body weight loss, stool
consistency alterations and bleeding, which peaked at day 8 and
decreased thereafter. At the end of the ﬁrst recovery phase
(ﬁfteenth day), the DAI score was reduced to control group levels
(Fig. 2A). During the second cycle of DSS, a faster new increase in
DAI score was observed, but it did not decrease after the recovery
phase to the basal level until day 30, indicating a possible
chroniﬁcation of intestinal inﬂammation (Fig. 2A). As observed in
Fig. 2B, body weight loss peaked at day 10 following the ﬁrst DSS
cycle, but at the end of the recovery phase, on day 15, body mass
was signiﬁcantly regained, presenting the same course as the DAI
score. After the second cycle of DSS, the animals lost weight
faster, but not in the same intensity as observed in the ﬁrst phase
and, differently from the DAI score, the body weight wasretrieved at the end of the second recovery phase (Fig. 2B).
Furthermore, in the ﬁrst cycle of DSS the colon was signiﬁcantly
shortened compared to the control group; while at the end of
ﬁfteenth day the colon length was signiﬁcantly restored (Fig. 2C).
However, after the second cycle of DSS colon was again
shortened until day 30 (Fig. 2C), suggesting chronic colonic
inﬂammation.
The MPO and EPO activities associated with DAI score and body
weight loss showed a signiﬁcant increase when assessed ﬁve days
after the beginning of DSS treatment (ﬁfth day), compared with the
control group. Similarly, at the end of the ﬁrst recovery phase
(ﬁfteenth day), MPO and EPO levels were reduced to control group
levels (Fig. 2D and E). The second cycle of DSS increased EPO
activity when compared with the control group, but induced a
greater increase in MPO activity, indicating possible aggravation of
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period with drinking water (thirtieth day), MPO activity was
signiﬁcantly decreased (compared with day 20), but nonetheless
its level was still greater than that of MPO activity observed in the
control group and even higher than the levels observed in the acute
phase, after the ﬁrst cycle of DSS (Fig. 2D), suggesting the
involvement of neutrophils in chronic intestinal inﬂammation as
well. EPO activity levels decreased after the second recovery phase,
and although levels were still greater than those of the control
group, this enhancement did not reach statistical signiﬁcance
(Fig. 2E).
Interestingly, no signiﬁcant increase was observed in the NAG
activity at the end of the ﬁrst DSS cycle, and no differences were
observed between DSS cycle 1 and the ﬁrst recovery phase. NAG
levels showed an increase only at the end of the second recovery
phase (thirtieth day) (Fig. 2F). These data suggest that mononu-
clear cells play a signiﬁcant role mainly in chronic stages of DSS-
induced colitis.
3.2. CD4+ and CD8+ T lymphocytes in mesenteric lymph node and
colonic regulatory T cell markers during DSS-induced colitis
To gain further insight into indirect measurement of colonic
cell inﬁltration of myeloid lineage, we performed the CD4+ andFig. 3. Population of CD4+ and CD8+ cells in mesenteric lymph node during DSS-induced 
and 30 days, according to the experimental protocol set out in the Materials and Methods
of CD4+ (y-axis) and CD8+ (x-axis). (B) Quantiﬁcation of CD4+ T cells in the different time 
the initiation of the experimental protocol. (C) Quantiﬁcation of CD8+ T cells in the differe
after the initiation of the experimental protocol. Data are reported as means  S.E.M. oCD8+ quantiﬁcation of T cells in mesenteric lymph nodes by ﬂow
cytometry during the different phases of DSS-induced colitis.
Animals were euthanized on days 5, 15, 20 or 30, as previously
described, and the mesenteric lymph nodes were removed for
analysis. The results for CD4+ and CD8+ T cells quantiﬁcation
showed that only at the thirtieth day after the experimental
protocol initiation was cell population signiﬁcantly increased
(Fig. 3A–C), suggesting the involvement of these inﬂammatory
cells during the chronic phases of intestinal inﬂammation.
Next we assessed the activation of CD4+ and CD8+ T
lymphocytes by performing the co-expression of CD25 cellular
marker through the double staining of CD4+CD25+ and CD8+CD25+.
The population of CD4+CD25+ T lymphocytes was signiﬁcantly
increased at the end of the second recovery phase (thirtieth day),
exactly when the CD4+ cells population was already elevated in the
mesenteric lymph nodes (Fig. 4A and B). The CD8+CD25+ cell
population did not increase in any period compared with the
control group (Fig. 4C and D).
There is a considerable amount of evidence indicating that
regulatory T lymphocytes (Treg) play a critical role in IBD, owing to
their effects on the regulation and maintenance of intestinal
mucosal homeostasis. Thus, we also performed colonic mRNA
quantiﬁcation for Treg characteristic markers FoxP3 and CD25 in
colonic tissue. The quantiﬁcation of both FoxP3 and CD25 wascolitis. The mesenteric lymph nodes from mice were removed at the end of 5, 15, 20
 section. (A) Representative dot plot from cells after DSS-induced colitis. Population
periods, demonstrating a signiﬁcant increase in T CD4+ cell population 30 days after
nt time periods that showed a signiﬁcant increase in T CD8+ cell population 30 days
f six to eight mice per group. #P < 0.05 versus control group.
Fig. 4. Population of CD4+CD25+ and CD8+CD25+ cells in mesenteric lymph node and colonic T regulatory cell markers during DSS-induced colitis. The mesenteric lymph
nodes from mice were removed at day 5, 15, 20 and 30 following the protocol initiation, as described in the Materials and Methods section. (A) Representative dot plot from
cells after DSS-induced colitis. Population of CD4+ (y-axis) and CD25+ (x-axis) that was used as an activation marker of T cells. (B) Quantiﬁcation of CD4+ CD25+ in the different
time periods showed a signiﬁcant increase in CD4+ CD25+ T cell population 30 days after the initiation of the experimental protocol. (C) Representative dot plot from cells after
DSS-induced colitis. Population of CD8+ (y-axis) and CD25+ (x-axis) that was used as an activation marker of T cells. (D) Quantiﬁcation of CD8+ CD25+ in the different time
periods did not show any difference in CD8+ CD25+ T cell population in the analyzed periods. In another set of experiments, colon tissue was collected and processed for real-
time PCR quantiﬁcation. (E) FoxP3 mRNA was gradually increased after the end of the ﬁrst recovery phase (ﬁfteenth day), until 30 days after the beginning of the DSS protocol.
(F) mRNA for CD25 marker also increased after the end of the ﬁrst recovery phase (ﬁfteenth day), until 30 days after the beginning of the DSS treatment. Data are reported as
means  S.E.M. of six to eight mice per group. #P < 0.05 versus control group, *P < 0.05 versus selected groups. NS = not signiﬁcant.
A.F. Bento et al. / Biochemical Pharmacology 84 (2012) 1459–14691464signiﬁcantly increased after the ﬁrst recovery phase (ﬁfteenth),
and showed a gradual increase until the end of the experimental
protocol (thirtieth day) (Fig. 4E and F). These data also suggest the
presence of regulatory T cells, especially in chronic phases of DSS-
induced colitis.
3.3. Cytokine protein levels in colonic tissue in acute and chronic DSS-
induced colitis
In order to analyze some of the inﬂammatory mediators
involved in colonic inﬂammation during DSS-induced colitis,
colons were removed at the end of day 5, 15, 20 and 30 after DSS
administration and further processed for cytokine production by
ELISA assay, as described in the Materials and Methods section. Our
results demonstrated a signiﬁcant increase in TNF levels in colon
tissue in all analyzed periods, compared with the control group,
especially in the acute phase of experimental colitis (ﬁfth day)
(Fig. 5A). Moreover, the colonic level of pro-inﬂammatory cytokine
IL-1b was signiﬁcantly increased after DSS cycle 2, and remained
elevated until the end of the second recovery phase (thirtieth day),
suggesting its possible role in chronic intestinal inﬂammation
(Fig. 5B). In addition, the levels of the pro-inﬂammatory cytokine
IL-12 and the chemokine CXCL1/KC were also measured as
mentioned above. The results showed that IL-12 levels were
signiﬁcantly increased only ﬁve days after the beginning of DSS
administration, compared with the control animals (Fig. 5C).
CXCL1/KC levels, however, showed a marked increase at the end of
both DSS induction phases (ﬁfth and twentieth days), but not in the
recovery periods (Fig. 5D).The tissue levels of the anti-inﬂammatory mediators IL-10, IL-4
and TGF-b were also evaluated in the colon alongside DSS-induced
colitis. Differently from the pro-inﬂammatory cytokine results, a
signiﬁcant increase in IL-10 production was observed at the end of
both recovery phases (ﬁfteenth and thirtieth days), and no change
was observed during the induction phase compared with the
control group (Fig. 5E). In addition, IL-4 quantiﬁcation presented a
signiﬁcant increase ﬁfteen days after the beginning of the DSS
regimen (ﬁrst recovery phase), but not in other analyzed periods
(Fig. 5F). Finally, the quantiﬁcation of TGF-b protein demonstrated
that its level was enhanced after the latest recovery phase (day 30)
compared with the control group (Fig. 5G). Notably, no signiﬁcant
differences were found for other periods analyzed for TGF-b levels
in comparison with control animals.
3.4. Investigation of mRNA expression for inﬂammatory mediators
and adhesion molecules during DSS-induced colitis
Since COX-2 plays a crucial role in the production of many lipid
mediators involved in intestinal inﬂammation and since lipoxin A4
receptor (ALX/FPR2) plays an important role in the resolution of
inﬂammation [13,14], we performed mRNA expression for these
proteins in colon tissue during acute and chronic phases of DSS-
induced colitis. Interestingly, the COX-2 mRNA expression was
signiﬁcantly increased in all analyzed time points, but showed a
stronger increase in the recovery phases of intestinal inﬂammation
(ﬁfteenth and thirtieth days) (Fig. 6A). On the other hand, ALX/
FPR2 mRNA expression showed a signiﬁcant increase only in the
DSS second induction phase (Fig. 6B).
Fig. 5. Determination of cytokines in colon tissue during experimental colitis induced by DSS. At day 5, 15, 20 and 30 following colitis induction, colon tissue was collected and
processed for cytokine levels by ELISA assay. (A) The tissue levels of TNF-a increased signiﬁcantly in all periods evaluated, particularly ﬁve days after the beginning of the DSS
treatment. (B) Quantiﬁcation of IL-1b in the colon showed a marked increase at the end of the second cycle of DSS (twentieth day), which remained elevated until the thirtieth
day. (C) The measurement of IL-12 increased just ﬁve days after the DSS treatment. (D) The levels of CXCL1/KC showed signiﬁcant increase at the end of cycle 1 (ﬁfth day) and
cycle 2 (twentieth day) of DSS. (E) IL-10 levels were signiﬁcantly increased at the end of the recovery phases (ﬁfteenth and thirtieth days). (F) Quantiﬁcation for IL-4 showed
an increase only on the ﬁfteenth day after the beginning of the DSS regimen. (G) TGF-b levels were signiﬁcantly increased at the end of the second recovery phase (thirtieth
day). Data are reported as means  S.E.M. of six to eight mice per group. #P < 0.05 versus control group. *P < 0.05 versus selected groups.
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tory cell inﬁltration in the colonic tissue, we next evaluated the
mRNA expression for adhesion molecules VCAM-1 and ICAM-1,
which are directly connected to cell transmigration in inﬂamed
colonic tissue [15]. Our results revealed a signiﬁcant increase of
VCAM-1 mRNA expression on the ﬁfth, twentieth and thirtieth
days after the start of DSS treatment compared with control
animals (Fig. 6C). Moreover, mRNA expression for ICAM-1 showed
a signiﬁcant increase only at the end of the second DSS cycle
(twentieth day), indicating its possible role in the later stages of
DSS-induced colitis (Fig. 6D). A pro-inﬂammatory cytokine IL-17
mRNA level was also measured in colonic tissue during experi-
mental colitis. The results showed elevated expression of IL-17
mRNA in all analyzed periods, and an especially strong increase at
the end of the DSS second cycle (Fig. 6E).
3.5. Activation of NFkB pathway in DSS-induced colitis
Many inﬂammatory mediators involved in the pathogenesis of
inﬂammatory bowel diseases are transcribed by the NFkB
signaling pathway. Therefore we evaluated the phosphorylated
protein expression for IkB-a (p-IkB-a) and p65 NFkB (p-p65
NFkB) by western blot. Our results showed that p-IkB-a was
increased after the ﬁrst recovery phase (ﬁfteenth day) compared
with the control group (Fig. 7A). Interestingly, its expression
increased gradually in the twentieth and thirtieth days after the
beginning of the DSS regimen, indicating possible increase of IkB-acleavage and consequent release of p65 subunit. Likewise, p-p65
NFkB is also increased gradually from the ﬁfteenth until the
thirtieth day after the DSS-colitis initiation (Fig. 7B).
4. Discussion
Over the past 20 years much research has highlighted the
importance of understanding the pathogenesis of IBD for the
development of efﬁcient and safe pharmacological treatments. In
this context, we investigated some of the immunological events
that occur during acute and chronic phases as well as the remission
period in the widely used experimental model of DSS-induced
colitis. Our results showed that in the ﬁrst recovery phase the
endeavor of the body to resolve inﬂammation resulted in a
complete decrease of the DAI, although some inﬂammatory
mediators did not reach basal levels. Therefore after the second
cycle with DSS, a greater increase and a different partner of
inﬂammatory mediators were observed. Although during the
second recovery phase a new effort of the body to compensate
inﬂammation was observed, the clinical parameters were still
present, demonstrating the chroniﬁcation of the process.
Our data demonstrated that the ﬁrst induction phase was
characterized by the inﬁltration of neutrophils and eosinophils but
not mononuclear cells to the colon. The relevance of eosinophils in
gut inﬂammation has been described by several authors [11,16–
18]. Nevertheless, our group and others have demonstrated a
major role of neutrophils in colonic tissue damage [11]. In fact,
Fig. 6. Evaluation of mRNA for colonic proteins during DSS-induced colitis. On day 5, 15, 20 and 30, colon tissue was collected and processed for real-time PCR. (A) The mRNA
levels for COX-2 increased signiﬁcantly in all periods, especially in the recovery phases (ﬁfteenth and thirtieth days). (B) ALX/FPR2 receptor mRNA levels increased only in the
second DSS cycle (twentieth day). (C) mRNA quantiﬁcation for adhesion molecule VCAM-1 increased ﬁve, 20 and 30 days after the beginning of the DSS regime. (D) ICAM-1
mRNA levels increased only in the second DSS cycle (twentieth day). (E) IL-17 levels increased in all analyzed periods, especially at the end of the DSS second cycle. Data are
reported as means  S.E.M. of six to eight mice per group. #P < 0.05 versus control group. *P < 0.05 versus selected groups.
Fig. 7. Phosphorylated IkB-a and NFkB expression during DSS-induced colitis. Analysis p-IkB-a and p-NFkB p65 expression was performed in the colon tissue by the western
blot method at different time points. (A) The protein expression of phosphorylated IkB-a was signiﬁcantly higher after the ﬁfteenth day, and gradually increased until the end
of the experimental protocol. (B) Quantiﬁcation of the activated p65 subunit of NFkB showed a similar result to the p-IkB-a expression, revealing an increase after the ﬁrst
recovery phase (ﬁfteenth day), until day 30. Data are reported as means  S.E.M. of six to eight mice per group. #P < 0.05 versus control group.
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diarrhea, stool bleeding and signiﬁcant weight loss, all known
signals of colon damage. Polymorphonuclear cell inﬁltration was
accompanied by the increase of the chemokine CXCL1/KC, which is
essential for neutrophil migration to the injury focus, and VCAM-1
that has been described as important for leukocyte adhesion and
inﬁltration during several inﬂammation conditions [15], e.g. DSS-
induced colitis [14].
In the acute inﬂammatory phase a signiﬁcant increase in levels
of IL-12, IL-17 and especially TNF-a was observed. In fact, all these
mediators are important for leukocyte activation and/or migration
[19–21]. It was shown that TNF-a and IL-17 are produced by
neutrophils and that TNF-a enhances IL-12 production [22,23].
Interestingly, in clinical practice, therapy with neutralizing
antibodies against both IL-12 and TNF cytokines improved IBD
[23,24]. Furthermore, knockout mice for IL-17A showed a
reduction in DSS-induced colitis severity [25], pointing to the
relevance of those cytokines for tissue damage.
At the end of the ﬁrst recovery phase, when animals appeared to
be healthy, the anti-inﬂammatory response could be observed by
the increase of both IL-10 and IL-4 levels. It has been demonstrated
that these cytokines act synergistically in the down-regulation of
chemokine production and in the function of lamina propria
mononuclear cells of IBD patients, leading a signiﬁcant improve-
ment of inﬂammatory symptoms [26,27]. This synergism seems to
be evident principally in the ﬁrst recovery phase, as we did not
observe any signiﬁcant increase of IL-4 colonic production in the
second recovery period.
The recovery phase was also characterized by a huge
enhancement of COX-2 expression. In fact, COX-2 expression
has already signiﬁcantly increased in the ﬁrst inﬂammatory phase,
where it might be important for pro-inﬂammatory eicosanoid
synthesis [13]. Nonetheless, our data suggest that this enzyme is
critical for inﬂammation resolution, probably because of the
formation of pro-resolution lipid mediators, according to previous
work [13]. It has been shown that COX-2 is associated with the
increase of the anti-inﬂammatory prostaglandin D2 (PGD2) [28],
which acts as a ‘‘stop signal,’’ reducing granulocyte inﬁltration in
experimental colitis [29].
In concert with the anti-inﬂammatory response and with
mice amelioration, MPO and EPO activities as well as KC and
VCAM-1 decreased to basal levels, reinforcing the inﬂuence of
those cells on colitis aggravation and highlighting the efﬁcacy of
the body’s anti-inﬂammatory response. IL-12 and TNF-a levels
also decreased; however, the anti-inﬂammatory effect could not
completely restore homeostasis since TNF and IL-17 remained
elevated compared with control groups. The maintenance of
those cytokine levels suggests that they are produced by cells
other than polymorphonuclear ones. Although we could not
observe any increase in lymphocyte inﬂux at the acute stage,
possible sources of IL-17 are the Paneth cells and resident T gd
cells [30,31]. The results identify both TNF-a and IL-17 as key
cytokines involved in the process of chroniﬁcation of intestinal
inﬂammation.
After the second cycle with DSS we could observe a faster new
increase in DAI score. Notably, the worsening of murine conditions
was found in concert with a new wave of polymorphonuclear cell
inﬁltration, CXCL1/KC and VCAM-1 expression. Indeed there was
an increase in neutrophil migration and VCAM-1 expression
compared with the ﬁrst induction phase. Also, in the late
inﬂammatory phase, the increase in the expression of ICAM-1,
an adhesion molecule relevant for eosinophil recruitment [32],
was detected. Interestingly, VCAM-1 is uniquely expressed by
activated endothelium [33], whereas ICAM-1 is expressed by
leukocytes and other cells being further up-regulated during
inﬂammation [34]. Thus, the increase of ICAM-1 levels in thesecond induction phase may at least in part be owed to higher
leukocyte inﬁltration. Interestingly, it has been suggested that in
acute phases TNF-a is largely responsible for the early up-
regulation of these adhesion molecules, whereas IL-1b enhances
the expression of VCAM-1 and ICAM-1 in late disease [35].
Differently from the ﬁrst inﬂammatory phase, in the second
one, high levels of IL-1b were observed. The TNF-a level remained
elevated although it did not suffer a second up-regulation. These
pro-inﬂammatory cytokines probably contribute to the worsening
of experimental colitis by enhancing neutrophil migration [36].
Also, a meaningful increase in IL-17 and decreased production of
IL-12 were observed, corroborating other studies showing the
inverse correlation between these cytokines [37]. Interestingly,
although many studies have highlighted the pro-inﬂammatory
action of IL-17 [25], others challenge this view [38]. Recently a
population of regulatory T cells able to produce this cytokine was
described [39]. Accordingly, even in this phase, we observed an
increase in FoxP3 expression, the major transcription factor of
regulatory T cells.
The receptor ALX/FRP2 is present in leukocytes and can be
activated by pro-resolution lipid mediators, including LXA4 and
resolvin D1 (RvD1) [40], but also by microbial peptides, exerting a
dual role in inﬂammation [14,40,41]. Notably, transcription of
ALXR/FRP2 has been shown to be up-regulated by various
cytokines, suggesting regulation of receptor expression in an
inﬂammatory milieu [42,43] and corroborating our ﬁnding of
increased ALX/FPR2 expression in the second DSS induction
phase. However, further studies are required to verify this
hypothesis.
In the second recovery phase, the inﬁltration of mononuclear
cells and increased levels of FoxP3, IL-10, TGF-b but not IL-4 levels
were detected in colon tissue. In addition, CD4+CD25+ lymphocytes
were observed in mesenteric Lymph nodes. These results support
the notion that Treg cells in mesenteric lymph node migrate to the
inﬂamed colonic mucosa and release signiﬁcant amounts of IL-10
and TGF-b. Although these components certainly account for the
decrease of inﬂammation [44], the resolution was not completely
achieved since TNF-a, IL1-b and IL-17 levels decreased but were
still elevated compared with the control group. Interestingly,
increased levels of IL-1b and TGF-b are known to enhance FoxP3
expression [45], The sustained level of pro-inﬂammatory cytokines
is probably related to the maintenance of elevated MPO activity
and therefore to tissue damage, since the DAI index was still
elevated, demonstrating that the animals did not recover totally
from the disease.
It is well established that the transcription of most pro-
inﬂammatory mediators is controlled by NFkB [46], NFkB
activation results from IkB protein phosphorylation by the IkB
kinase (IKK) complex, which in turn results in IkB ubiquitylation
following degradation [47]. Nevertheless, our data showed that
both p-IkB and p-p65-NFkB gradually increased from the ﬁrst
recovery phase onwards, suggesting a critical role of the NFkB
pathway in the up-regulation of cytokines, chemokines and
adhesion molecules during intestinal inﬂammation.
In conclusion, our present data revealed different chemical
inﬂammatory mediators and cell inﬂux in the acute and chronic
phases of intestinal inﬂammation caused by DSS. Although the
predominance of pro-inﬂammatory response was observed in
both induction phases, pro-resolution mediators were evident
during the recovery phases. Interestingly, we identiﬁed TNF-a
and IL-17 as key mediators that were still present after the ﬁrst
recovery phase and seemed to contribute to the greater
inﬂammatory response observed in the second induction phase.
In addition, our results revealed an imbalance between pro- and
anti-inﬂammatory responses in the late recovery period which
impaired the complete resolution of inﬂammation and tissue
Fig. 8. Inﬂammatory events during acute and chronic DSS-induced colitis. An acute
inﬂammatory response was initiated during the ﬁrst induction phase with DSS
(cycle 1), reﬂected in an increase in the disease activity index. (A) The increase of
inﬂammatory response is accompanied by increased expression/production of
certain inﬂammatory mediators and massive inﬁltration of leukocytes, such as
neutrophils and eosinophils. (B) The reduction of the disease activity is
accompanied by increased production of anti-inﬂammatory mediators, reduction
of cellular inﬁltration and production/expression of pro-inﬂammatory mediators.
(C) The DSS new cycle restarts the increase of inﬂammatory response and disease
activity index, leading to a greater increase in neutrophil inﬁltration and production
of several inﬂammatory mediators not observed in the acute phase. (D) In the
second recovery phase, colonic tissues are full of a variety of pro-and anti-
inﬂammatory mediators and mononuclear cells (macrophages and lymphocytes),
which were not present in other phases.
A.F. Bento et al. / Biochemical Pharmacology 84 (2012) 1459–14691468repair (see scheme in Fig. 8). Thus, our study contributes to better
understanding of the DSS colitis model and reinforces the
relevance of understanding the underlying mechanisms associ-
ated with the pathogenesis of experimental colitis for develop-
ment of relevant therapeutic interventions in human IBD.
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